



NeoTherapeutics Regains Compliance with NASDAQ Minimum Bid Requirement

Thursday September 26, 11:54 am ET

IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOTD) announced today that NASDAQ has notified the Company that it has regained compliance with NASDAQ's minimum bid price per share (\$1.00) requirements for continued listing on the NASDAQ National Market.

NeoTherapeutics seeks to create value for shareholders through the in-licensing and commercialization of anti-cancer drugs and the discovery and out-licensing of drugs for central nervous system disorders. Satraplatin, the Company's lead oncology drug, is being prepared for phase 3 study. Additional anti-cancer drugs are in phase 1 and 2 stages of development for bladder cancer and non-Hodgkin's lymphoma. The Company has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, dementia, mild cognitive impairment and pain. For additional information visit the Company's web site at www.neot.com.

This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.

Contact:
John McManus
NeoTherapeutics Inc.
(949) 788-6700 ext. 247